Literature review · Immune & inflammation

VIP (vasoactive intestinal peptide)

VIP research spans immune mechanisms and clinical trials of synthetic VIP, aviptadil. A positive experimental arthritis study does not outweigh the absence of benefit in a sizeable COVID-19 respiratory-failure trial.

By HeartPep · Reviewed · 2 selected source records

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

At a glance

Animal inflammation research and a human respiratory-disease trial answer different questions. The selected human trial was stopped for futility and did not demonstrate improved clinical outcomes, so mechanistic plausibility alone is insufficient.

Identity & scope

VIP denotes vasoactive intestinal peptide. The cited human trial used a specified intravenous aviptadil study formulation; its results cannot establish the properties of a supplier vial or nasal product.

Catalogue labels covered: VIP.

What the research shows

  • Delgado and colleagues reported reduced inflammatory and joint outcomes in experimental mouse arthritis.
  • The TESICO trial found no significant improvement in its 90-day clinical outcome with aviptadil versus placebo.

Critical interpretation

Mechanism and clinical outcome can diverge

A candidate can alter inflammatory pathways in a model without producing a detectable benefit in a particular human disease. The mouse arthritis experiment and the aviptadil respiratory trial should therefore not be pooled as though they measured the same effect. Our interpretation is that the mechanistic study motivates a hypothesis, while the clinical trial tests a specified intervention in a specified setting. [1] [2]

Futility is not a universal biological verdict

TESICO stopped the aviptadil comparison because continued enrolment was unlikely to establish the planned benefit. That does not answer every conceivable VIP question. It does mean the trial should remain visible when discussing clinical translation, rather than citing pathway rationale as if no substantive human test existed. The estimated effect and uncertainty are more informative than a simple success or failure label. [2]

Track the actual randomised comparison

The master protocol allowed participants to enter more than one treatment comparison. A researcher should extract the relevant comparator, analysis population and prespecified outcome for aviptadil itself, not transfer results from the separate remdesivir comparison. Further translational work would need an explicit disease rationale and formulation match, followed by independently reproduced patient-important outcomes. [2]

Limitations & uncertainties

  • Mouse arthritis is not a clinical test in people with rheumatoid arthritis.
  • TESICO concerns a specific severe infection context and studied formulation, not all possible VIP applications.
  • Neither source supports general immune enhancement, self-administration, or equivalence of catalogue nasal and vial products.

Open research questions

  • Which mechanistic findings reproduce independently and translate into prespecified human benefits?
  • How do formulation and exposure affect the interpretation of future studies?

Selected papers & source records

Download bibliography
Animal studyNamed compoundAbstract / record checked

1. Vasoactive intestinal peptide prevents experimental arthritis by downregulating both autoimmune and inflammatory components of the disease (opens in a new tab)

Delgado M, Abad C, Martinez C, Leceta J, Gomariz RP (2001). Nature Medicine. DOI: 10.1038/87887 (opens in a new tab) · PMID 11329057

Design & population
Experimental mouse arthritis study examining disease severity, joint damage and inflammatory/autoimmune pathways.
What the study found
Reported lower arthritis severity and changes in inflammatory and autoimmune components in the model.
Limits on interpretation
Preclinical disease model, not evidence of an effective rheumatoid-arthritis treatment in humans.
Human studyNamed compoundFull text consulted

2. Intravenous aviptadil and remdesivir for treatment of COVID-19-associated hypoxaemic respiratory failure in the USA (TESICO): a randomised, placebo-controlled trial (opens in a new tab)

Brown SM, Barkauskas CE, Grund B, et al. (2023). The Lancet Respiratory Medicine. DOI: 10.1016/S2213-2600(23)00147-9 (opens in a new tab) · PMID 37348524

Design & population
Multicentre randomised placebo-controlled trial; 461 participants received at least part of aviptadil or its matched placebo.
What the study found
No significant improvement in the primary 90-day ordinal clinical outcome or mortality; the aviptadil trial was stopped for futility.
Limits on interpretation
Disease-specific clinical study. It does not validate a catalogue formulation or establish benefits in other conditions.

Search & review scope

Targeted primary-record review using PubMed, PMC and publisher records, starting with existing HeartPep references and selected additional searches.. Checked 9 November 2026.

Mouse arthritis and TESICO human aviptadil trial. Full-text stopping rules and statistical analysis sections of TESICO consulted. No comprehensive indication-level search.

Selected narrative evidence review, not a systematic search or meta-analysis. Abstract-led unless an individual record is marked full-text. No claim that all studies, registries or unpublished results were searched. Linked notices and targeted correction/retraction searches were checked where accessible. This is not a complete publication-status or raw-data audit; missing search results do not certify that a paper has no updates.

Recorded search terms
  • site:pubmed.ncbi.nlm.nih.gov vasoactive intestinal peptide aviptadil randomized trial COVID 2023 TESICO
  • "37348524" aviptadil "10." Brown
  • "10.1038/87887" correction retraction
  • "10.1016/S2213-2600(23)00147-9" correction retraction

Read the collection’s methods and editorial limits. For formal research, assess and cite the original paper.

Cite this review

HeartPep. VIP (vasoactive intestinal peptide): literature review. HeartPep literature library. Reviewed 9 November 2026. https://heartpep.com/uk/research/library/vip.

HeartPep is the commercial publisher of this secondary summary. It is not a peer-reviewed primary paper. Cite the original studies for their findings.

Buy from HeartPep.com

Laboratory research only. Not for human or veterinary use.

← All reviews and reference notes